Summary:
- Researchers at Washington University School of Medicine in St. Louis have developed a new drug that can reduce the side effects of a type of stem cell transplant called a haploidentical or "half-matched" transplant.
- The drug, called PTCy (post-transplantation cyclophosphamide), helps prevent a potentially life-threatening complication called graft-versus-host disease (GVHD), where the donor's immune cells attack the recipient's healthy tissues.
- The study found that the use of PTCy significantly reduced the incidence of severe GVHD in patients who received a half-matched stem cell transplant, potentially making this treatment option more accessible to a wider range of patients.